Repurposed drugs and your IP strategy

September 1, 2011Biovista Articles

Using examples of drugs and companies, Dr Andreas Persidis gives tips on how to establish a systematic drug repositioning programme. Online article in the Managing Intellectual Property website. In the absence of productive internal R&D sufficient to support growth, current pharmaceutical IP strategies focus on acquiring smaller biotechs with promising assets to bolster larger pharma’s … Read More

Every drug deserves a second chance

September 1, 2011Biovista Articles

Guest Commentary in Drug Discovery News (DDN) by Andreas Persidis September 2011 After many years of talking about it, the patent cliff is finally with us in a big way. Starting with Pfizer’s Lipitor this coming November, Big Pharma is projected to lose more than $60 billion in the next five to six years from … Read More

Undercover COSS

June 8, 2011Biovista Articles

Biovista’s drug safety search aids clinical outcomes. Interview to Bio-IT World By Kevin Davies June 8, 2011 | Biovista began as a hobby,” admits the company’s eloquent president, Aris Persidis. But after “dabbling” with the firm for a few years, Persidis incorporated the company in the United States in 2005. Headquartered in Charlottesville, Virginia, Biovista … Read More

Biovista to present at the Drug Repositioning Conference

June 3, 2011Events

CHARLOTTESVILLE, Virginia, June 3, 2011 — Biovista announced today that it is presenting at the Drug Repositioning Conference, San Francisco, on July 13 2011. Biovista’s President, Dr. Aris Persidis, will give a presentation on systematic repositioning using Mechanism of Action. The Drug Repositioning Conference is one of the prime events in this space and has been … Read More